Glenmark Pharmaceuticals announces first in the world launch of its novel, globally-researched, latest-in-class diabetes medicine “Remogliflozin” in India
Udaipur : Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global integrated pharmaceutical company, today announced the launch of its novel,patent protected and globally-researched sodium glucose co-transporter (SGLT2)inhibitor Remogliflozinetabonate (Remogliflozin) in India. The drug is indicated in the treatment of type-2 diabetes mellitus in adults. SGLT2 inhibitors are novel anti-diabetic drugs that help achieve glycemic control by … Read more